Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S.

Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the ...

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said ...

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...

(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S ...

Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...